OBJECTIVES: The aim of this analysis is to compare the reimbursement rates for administration costs of triplet therapy bevacizumab-cisplatin-gemcitabine (BCG) versus doublet therapy cisplatin-pemetrexed (CP) for mNSCLC patients in France and German health care systems. METHODS: A systematic literature search performed in Medline, Embase, Cochrane, and Centre of Reviews and Dissemination databases identified 578 publications of anticancer agents. In addition, an evaluation of national reimbursement tariffs in both inpatient and outpatient settings was performed. Country-specific reimbursement structures were verified by two in-depth semi-structured expert oncologist interviews in each country. RESULTS: No publication including reimbursement tariffs for the administration of anticancer agents was identified during the systematic literature review. The evaluation of the national reimbursement tariffs showed significant costs for the administration service. The French GHS # 9606 “Chimiothérapie pour tumeur, en séances” is the reimbursement tariff of one inpatient chemotherapy session valued at €385.77 (public sector). The chemotherapy home infusion tariff code “chemotherapy, intravenous treatment” is valued at €374.16 irrespective of the number of injections administered. In Germany the inpatient reimbursement tariff G-DRG # E71B “Neubildung der Atmungsorgane” refers to the indication “neoplasm” with a cost of €1.671 for an inpatient visit and €610.40 for an outpatient visit. In both reimbursement systems these are flat rates irrespective of the number of chemotherapeutic drugs administered. CONCLUSIONS: When comparing the reimbursement for administrations of anticancer treatment combinations in France and Germany administration costs are unaffected by single, double or triple chemotherapy combinations. Therefore there is no difference in the cost of reimbursement for administration for BCG versus CP.